Analytical Data
-
基因名
IL31RA
- Application
-
别名
Interleukin-31 receptor subunit alpha; IL-31R-alpha; IL-31RA; GLM-R; GLM-R; CRL3
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-hFc
-
纯度
> 90% as determined by SDS-PAGE.
-
蛋白编号
Q8NI17
-
表达区间
A20-E519
-
分子量
120-170 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Related Products
Protein Description
IL-31RA (Interleukin-31 Receptor A) is a crucial component of the IL-31 signaling pathway, which is implicated in various inflammatory and allergic conditions, particularly in skin diseases such as atopic dermatitis. IL-31, a cytokine produced predominantly by Th2 cells, binds to IL-31RA, initiating a cascade of signaling events that contribute to pruritus (itching), inflammation, and other pathological responses. The receptor's expression is notably observed in epithelial cells, immune cells, and neurons, highlighting its role in mediating the effects of IL-31 in different tissues. Due to its involvement in inflammatory diseases, IL-31RA has emerged as a potential therapeutic target for interventions aimed at alleviating itching and inflammation. Research on recombinant IL-31RA proteins focuses on understanding their structure, function, and interaction with IL-31, enabling the development of targeted therapies that can block this pathway. Additionally, the exploration of IL-31RA as a biomarker for disease severity in atopic conditions could provide further insights into personalized treatment approaches. Overall, the study of IL-31RA recombinant proteins holds promise for advancing our understanding of immune-mediated diseases and improving clinical outcomes for patients suffering from chronic inflammatory conditions.
